Differential response of MC3T3-E1 and human mesenchymal stem cells to inositol hexakisphosphate

Cellular Physiology and Biochemistry

Volumn 30, Issue 4, 2012, Pages 974-986

  Del Mar Arriero, María ^a   Ramis, Joana M ^a   Perelló, Joan ^b   Monjo, Marta ^a  

^a UNIVERSITAT DE LES ILLES BALEARS   (Spain)

^b Laboratoris Sanift   (Spain)

Author keywords

Gene expression; Human umbilical cord mesenchymal stem cells (hUC MSCs); Inositol hexakisphosphate; IP6 kinase inhibitor; Mineralization; Osteoblast; Phytic acid

Indexed keywords

ALKALINE PHOSPHATASE; MESSENGER RNA; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; OSTEOPROTEGERIN; PHYTIC ACID; TRANSCRIPTION FACTOR RUNX2;

ANIMAL CELL; BIOMINERALIZATION; BONE MINERALIZATION; CELL DIFFERENTIATION; CELL STRUCTURE; CELL TYPE; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSSIFICATION; OSTEOBLAST; OSTEOPOROSIS; PARACRINE SIGNALING; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; TARGET CELL; UMBILICAL CORD;

EID: 84870325745     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000341474     Document Type: Review

References (50)

1. Li B, Ling Chau JF, Wang X, Leong WF: Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy. J Cell Biochem 2011;112:1229-1242.
2. Horst-Sikorska W, Wawrzyniak A: The role of hormonal therapy in osteoporosis. Endokrynol Pol 2011;62:61-64.
3. Knopp-Sihota JA, Newburn-Cook CV, Homik J, Cummings GG, Voaklander D: Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures: A systematic review and meta-analysis. Osteoporos Int 2012;23:17-38.
4. Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HA, Recker RR, Harris ST, Wu W, Genant HK, Black DM, Eastell R: Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609-3617. (Pubitemid 34879503)
5. Han SL, Wan SL: Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: Meta-analysis of randomised controlled trials. Int J Clin Pract 2012;66:199-209.
6. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-765.
7. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E: Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the american society for bone and mineral research. J Bone Miner Res 2007;22:1479-1491. (Pubitemid 351229318)
8. Woo SB, Hellstein JW, Kalmar JR: Narrative [corrected] review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-761. (Pubitemid 46780635)
9. Strampel W, Emkey R, Civitelli R: Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug safety 2007;30:755-763. (Pubitemid 47351214)
10. Baron R, Hesse E: Update on bone anabolics in osteoporosis treatment: Rationale, current status, and perspectives. J Clin Endocrinol Metab 2012;97:311-325.
11. Arriero M, Ramis JM, Perelló J, Monjo M: Inositol hexakisphosphate inhibits osteoclastogenesis on raw 264.7 cells and human primary osteoclasts. PLOs ONE 2012;7:e43187.
12. Irvine RF, Schell MJ: Back in the water: The return of the inositol phosphates. Nat Rev Mol Cell Biol 2001;2:327-338. (Pubitemid 33674045)
13. Raboy V: Myo-inositol-1, 2, 3, 4, 5, 6-hexakisphosphate. Phytochemistry 2003;64:1033-1043.
14. Vallejo M, Jackson T, Lightman S, Hanley MR: Occurrence and extracellular actions of inositol pentakis-and hexakisphosphate in mammalian brain. Nature 1987;330:656-658. (Pubitemid 18005580)
15. Bunce CM, French PJ, Allen P, Mountford JC, Moor B, Greaves MF, Michell RH, Brown G: Comparison of the levels of inositol metabolites in transformed haemopoietic cells and their normal counterparts. Biochem J 1993;289:667-673. (Pubitemid 23074947)
16. Grases F, Simonet BM, Prieto RM, March JG: Phytate levels in diverse rat tissues: Influence of dietary phytate. Br J Nutr 2001;86:225-231. (Pubitemid 32780628)
17. Lopez-Gonzalez AA, Grases F, Perello J, Tur F, Costa-Bauza A, Monroy N, Mari B, Vicente-Herrero T: Phytate levels and bone parameters: A retrospective pilot clinical trial. Front Biosci (Elite Ed) 2010;2:1093-1098.
18. Grases F, Sanchis P, Prieto RM, Perello J, Lopez-Gonzalez AA: Effect of tetracalcium dimagnesium phytate on bone characteristics in ovariectomized rats. J Med Food 2010;13:1301-1306.
19. Addison WN, McKee MD: Inositol hexakisphosphate inhibits mineralization of mc3t3-e1 osteoblast cultures. Bone 2010;46:1100-1107.
20. Shears SB: How versatile are inositol phosphate kinases? Biochem J 2004;377:265-280. (Pubitemid 38142182)
21. Ramis JM, Rubert M, Vondrasek J, Gaya A, Lyngstadaas SP, Monjo M: Effect of enamel matrix derivative and of proline-rich synthetic peptides on the differentiation of human mesenchymal stem cells toward the osteogenic lineage. Tissue Eng Part A 2012;18:1253-1263
22. Padmanabhan U, Dollins DE, Fridy PC, York JD, Downes CP: Characterization of a selective inhibitor of inositol hexakisphosphate kinases: Use in defining biological roles and metabolic relationships of inositol pyrophosphates. J Biol Chem 2009;284:10571-10582.
23. Chiu R, Smith KE, Ma GK, Ma T, Smith RL, Goodman SB: Polymethylmethacrylate particles impair osteoprogenitor viability and expression of osteogenic transcription factors runx2, osterix, and dlx5. J Orthopaed Res 2010;28:571-577.
24. Sodek J, Ganss B, McKee MD: Osteopontin. Crit Rev Oral Biol Med 2000;11:279-303.
25. Kazanecki CC, Uzwiak DJ, Denhardt DT: Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J Cell Biochem 2007;102:912-924. (Pubitemid 350036931)
26. Zhu B, Suzuki K, Goldberg HA, Rittling SR, Denhardt DT, McCulloch CA, Sodek J: Osteopontin modulates cd44-dependent chemotaxis of peritoneal macrophages through g-protein-coupled receptors: Evidence of a role for an intracellular form of osteopontin. J Cell Physiol 2004;198:155-167. (Pubitemid 38120976)
27. Sezer O, Heider U, Zavrski I, Kuhne CA, Hofbauer LC: Rank ligand and osteoprotegerin in myeloma bone disease. Blood 2003;101:2094-2098. (Pubitemid 36302042)
28. Quarles LD, Yohay DA, Lever LW, Caton R, Wenstrup RJ: Distinct proliferative and differentiated stages of murine mc3t3-e1 cells in culture: An in vitro model of osteoblast development. J Bone Miner Res 1992;7:683-692.
29. Macchiarini P, Jungebluth P, Go T, Asnaghi MA, Rees LE, Cogan TA, Dodson A, Martorell J, Bellini S, Parnigotto PP, Dickinson SC, Hollander A P, Mantero S, Conconi MT, Birchall MA: Clinical transplantation of a tissue-engineered airway. Lancet 2008;372:2023-2030.
30. Hofbauer LC, Schoppet M: Clinical implications of the osteoprotegerin/rankl/rank system for bone and vascular diseases. J Am Med Assoc 2004;292:490-495. (Pubitemid 38988958)
31. Reszka AA, Rodan GA: Nitrogen-containing bisphosphonate mechanism of action. Mini Rev Med Chem 2004;4:711-719. (Pubitemid 39149473)
32. Rodan G, Reszka A, Golub E, Rizzoli R: Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin 2004;20:1291-1300. (Pubitemid 39120794)
33. Rogers MJ: New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003;9:2643-2658. (Pubitemid 37456015)
34. Rogers MJ, Watts DJ, Russell RG: Overview of bisphosphonates. Cancer 1997;80:1652-1660. (Pubitemid 27444037)
35. Lopez-Gonzalez AA, Grases F, Mari B, Vicente-Herrero MT, Costa-Bauza A, Monroy N: The influence of consumption of phytate on the bone mass in posmenopausal women of mallorca. Reumatol Clin 2011;7:220-223.
36. Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, Spelsberg TC: Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 2000;60:6001-6007.
37. Igarashi K, Hirafuji M, Adachi H, Shinoda H, Mitani H: Effects of bisphosphonates on alkaline phosphatase activity, mineralization, and prostaglandin e2 synthesis in the clonal osteoblast-like cell line mc3t3-e1. Prostaglandins Leukot Essent Fatty Acids 1997;56:121-125. (Pubitemid 27076242)
38. Bellows CG, Aubin JE, Heersche JN: Initiation and progression of mineralization of bone nodules formed in vitro: The role of alkaline phosphatase and organic phosphate. Bone Miner 1991;14:27-40.
39. Fujita H, Kurokawa K, Ogino T, Ono M, Yamamoto M, Oka T, Nakanishi T, Kobayashi N, Tanaka N, Ogawa T, Suzaki E, Utsumi K, Sasaki J: Effect of risedronate on osteoblast differentiation, expression of receptor activator of nf-kappab ligand and apoptosis in mesenchymal stem cells. Basic Clin Pharmacol Toxicol 2011;109:78-84.
40. Von Knoch F, Jaquiery C, Kowalsky M, Schaeren S, Alabre C, Martin I, Rubash HE, Shanbhag AS: Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials 2005;26:6941-6949. (Pubitemid 41095518)
41. Duque G, Rivas D: Alendronate has an anabolic effect on bone through the differentiation of mesenchymal stem cells. J Bone Miner Res 2007;22:1603-1611. (Pubitemid 351229330)
42. Im GI, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS: Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 2004;25:4105-4115. (Pubitemid 38388576)
43. Menniti FS, Miller RN, Putney JW Jr, Shears SB: Turnover of inositol polyphosphate pyrophosphates in pancreatoma cells. J Biol Chem 1993;268:3850-3856. (Pubitemid 23072913)
44. Stephens L, Radenberg T, Thiel U, Vogel G, Khoo KH, Dell A, Jackson TR, Hawkins PT, Mayr GW: The detection, purification, structural characterization, and metabolism of diphosphoinositol pentakisphosphate (s) and bisdiphosphoinositol tetrakisphosphate (s). J Biol Chem 1993;268:4009-4015. (Pubitemid 23072933)
45. Chakraborty A, Kim S, Snyder SH: Inositol pyrophosphates as mammalian cell signals. Sci Signal 2011;4:e1.
46. Bennett M, Onnebo SM, Azevedo C, Saiardi A: Inositol pyrophosphates: Metabolism and signaling. Cell Mol Life Sci 2006;63:552-564.
47. Grases F, Simonet BM, March JG, Prieto RM: Inositol hexakisphosphate in urine: The relationship between oral intake and urinary excretion. BJU Int 2000;85:138-142. (Pubitemid 30072465)
48. Szwergold BS, Graham RA, Brown TR: Observation of inositol pentakis-and hexakis-phosphates in mammalian tissues by 31p nmr. Biochem Biophys Res Commun 1987;149:874-881.
49. Grases F, Isern B, Perello J, Sanchis P, Prieto RM, Costa-Bauza A: Absorption of myo-inositol hexakisphosphate (insp6) through the skin in humans. Pharmazie 2006;61:652. (Pubitemid 44098038)
50. Lopez-Gonzalez AA, Grases F, Roca P, Mari B, Vicente-Herrero MT, Costa-Bauza A: Phytate (myo-inositol hexaphosphate) and risk factors for osteoporosis. J Med Food 2008;11:747-752.